Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this space. Eli Lilly, AbbVie, AstraZeneca and more are up for the challenge.
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle Read More »
